Secondary cytoreductive surgery in the patient with recurrent ovarian cancer is often beneficial
AE Selman, LJ Copeland - Critical reviews in oncology/hematology, 2002 - Elsevier
AE Selman, LJ Copeland
Critical reviews in oncology/hematology, 2002•ElsevierThe majority of women with ovarian cancer will present at an advanced stage and ultimately
experience a recrudescence of tumor. Recent data indicates that secondary cytoreductive
surgery is feasible, well tolerated and associated with significant prolongation of survival in
selected patients with recurrent ovarian cancer.
experience a recrudescence of tumor. Recent data indicates that secondary cytoreductive
surgery is feasible, well tolerated and associated with significant prolongation of survival in
selected patients with recurrent ovarian cancer.
The majority of women with ovarian cancer will present at an advanced stage and ultimately experience a recrudescence of tumor. Recent data indicates that secondary cytoreductive surgery is feasible, well tolerated and associated with significant prolongation of survival in selected patients with recurrent ovarian cancer.
Elsevier